Skip to main content

Table 1 Patient baseline characters

From: Distant survival for patients undergoing surgery using volatile versus IV anesthesia for hepatocellular carcinoma with portal vein tumor thrombus: a retrospective study

Variables TIVA (N = 208) INHA (N = 263) P value
  N (%) N (%)  
Sex (male) 188 (90.4) 239 (90.9) 0.856
HBsAg − +a 182 (87.5) 226 (85.9) 0.619
ASA
 II 186 (89.4) 229 (87.1) 0.191
 III 22 (10.6) 30 (11.4)  
 IV 0 (0) 4 (1.5)  
Child-Pugh
 A 184 (88.5) 233 (88.6) 0.662
 B 22 (10.6) 25 (9.5)  
 C 2 (0.4) 5 (1.1)  
AFP (ug/L)
 < 25 30 (14.4) 54 (20.5) 0.109
 25–399 39 (18.8) 45 (17.1)  
 400–999 12 (5.8) 25 (9.5)  
 ≥ 1000 127 (61.1) 139 (52.9)  
Tumor Diameter (cm)
 < 5 1 (0.4) 2 (0.8) 0.546
 5–9.9 22 (10.6) 36 (13.7)  
 ≥ 10 185 (88.9) 225 (85.6)  
PVTT
 1 30 (14.4) 40 (15.3) 0.716
 2 131 (63.0) 163 (62.0)  
 3 47 (22.1) 60 (22.8)  
Year of surgery
 2008 70 (33.7) 79 (30.0) 0.882
 2009 33 (15.9) 42 (16.0)  
 2010 31 (14.9) 46 (17.5)  
 2011 31 (14.9) 37 (14.1)  
 2012 43 (20.7) 59 (22.4)  
  Mean (SD) Mean (SD)  
Age (yr) 48.0 (10.94) 49.0 (9.73) 0.078
  Median (IQR) Median (IQR)  
WBC (109/L) 5.5 (4.2, 7.3) 5.4 (4.3, 7.1) 0.06
ALT (U/L) 47.8 (31.0, 66.0) 45.0 (29.1, 67.3) 0.903
AST (U/L) 49.0 (37.0, 69.0) 52.0 (35.0, 71.0) 0.820
  1. ASA American Society of Anesthesiologists, PVTT Portal vein tumor thrombus, INHA Volatile inhalational anesthesia, TIVA Total IV anesthesia, WBC White blood cells, NLR Neutrophil–lymphocytes ratio
  2. a Including 4 patients with HBsAg− + and anti-HCV − +